As we have previously reported, the American Diabetes Association (ADA) has asked all pharmaceutical companies involved in the development or marketing of incretin-based medications (Januvia/Janumet/Byetta/Victoza) to make patient level data on their products available for an independent review. Research into the safety of these incretin medications continues across the globe.
A recent study published in the medical journal, Expert Opinion on Drug Safety, confirms other U.S. studies that link incretin mimetic medications to pancreatic damage. The researchers from Ferrara, Italy, looked at 1,169 adverse drug reaction reports that concerned incretin mimetics and found 90 instances of pancreatitis and elevated pancreatic enzymes, with more than a third of those cases serious. This raises concerns that cases of chronic pancreatitis may lead to pancreatic cancer among some users.
If you or a loved one have suffered from pancreatitis or pancreatic cancer after taking Januvia/Janumet, Byetta or Victoza, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any potential claims.